Exelixis, Inc. - Common Stock (EXEL)
44.92
-0.48 (-1.06%)
NASDAQ · Last Trade: May 19th, 12:04 PM EDT
Detailed Quote
Previous Close | 45.40 |
---|---|
Open | 45.40 |
Bid | 44.90 |
Ask | 44.94 |
Day's Range | 44.80 - 46.22 |
52 Week Range | 20.14 - 48.85 |
Volume | 961,244 |
Market Cap | 14.15B |
PE Ratio (TTM) | 20.42 |
EPS (TTM) | 2.2 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,446,219 |
Chart
About Exelixis, Inc. - Common Stock (EXEL)
Exelixis Inc is a biopharmaceutical company focused on developing innovative therapies for patients with cancer. The company primarily engages in the discovery, development, and commercialization of small molecule drugs that target key pathways involved in cancer cell growth and survival. Through its research and clinical development programs, Exelixis aims to provide effective treatment options that improve patient outcomes and enhance the quality of life for individuals battling various forms of cancer. The company's commitment to oncology is evident in its robust pipeline of investigational drugs and its ongoing collaborations with other organizations in the healthcare sector. Read More
News & Press Releases
Large-cap stocks surged in the last week. CoreWeave, Super Micro, Coinbase, NRG Energy, Astera Labs, First Solar, Exelixis, Rocket Lab, Hims & Hers, On Holding and Gap were the top performers.
Via Benzinga · May 18, 2025
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before considering an investment.
Via Chartmill · May 17, 2025
Exelixis lifts 2025 revenue outlook after strong Q1 driven by Cabometyx sales surge and early traction in the neuroendocrine tumor market.
Via Benzinga · May 14, 2025
Nasdaq 100 rises further as Nvidia and AMD rally on Middle East investment hopes, while gold tumbles and Treasury yields surge.
Via Benzinga · May 14, 2025
Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628.
Via Benzinga · May 14, 2025
The top-notch biotech company easily beat first-quarter profit expectations.
Via Investor's Business Daily · May 13, 2025
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
By Exelixis, Inc. · Via Business Wire · May 13, 2025
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May:
By Exelixis, Inc. · Via Business Wire · May 7, 2025
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate
Via Chartmill · May 1, 2025
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
By Exelixis, Inc. · Via Business Wire · April 29, 2025
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Via Chartmill · April 28, 2025
A fundamental and technical analysis of (NASDAQ:EXEL): Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.
Via Chartmill · April 25, 2025
Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL).
Via Chartmill · April 16, 2025
Based on a technical and fundamental analysis of NASDAQ:EXEL we can say: EXELIXIS INC (NASDAQ:EXEL), a strong growth stock, setting up for a breakout.
Via Chartmill · April 14, 2025
EXELIXIS INC was identified as a growth stock that isn't overvalued. NASDAQ:EXEL is excelling in various growth indicators while maintaining a solid financial footing.
Via Chartmill · April 5, 2025
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price.
Via Chartmill · April 3, 2025